M. Chauvenet, V. Cottet, C. Lepage, V. Jooste, J. Faivre et al., Trends in colorectal cancer incidence: a period and birth-cohort analysis in a well-defined French population, BMC Cancer, vol.8, issue.3, p.282, 2011.
DOI : 10.1097/00008469-199906000-00011
URL : https://hal.archives-ouvertes.fr/inserm-00613110

. La-situation-du-cancer-en-france, http://www.e-cancer.fr/ Collection Rapports et synthèses, 2010.

M. Colonna, G. Hedelin, J. Esteve, P. Grosclaude, G. Launoy et al., National cancer prevalence estimation in France, International Journal of Cancer, vol.154, issue.2, pp.301-304, 2000.
DOI : 10.1002/1097-0215(20000715)87:2<301::AID-IJC24>3.0.CO;2-Y

C. Fuchs, J. Marshall, E. Mitchell, R. Wierzbicki, V. Ganju et al., Randomized, Controlled Trial of Irinotecan Plus Infusional, Bolus, or Oral Fluoropyrimidines in First-Line Treatment of Metastatic Colorectal Cancer: Results From the BICC-C Study, Journal of Clinical Oncology, vol.25, issue.30, pp.4779-4786, 2007.
DOI : 10.1200/JCO.2007.11.3357

H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth et al., Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer, New England Journal of Medicine, vol.350, issue.23, pp.2335-2342, 2004.
DOI : 10.1056/NEJMoa032691

L. Saltz, S. Clarke, E. Diaz-rubio, W. Scheithauer, A. Figer et al., Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study, Journal of Clinical Oncology, vol.26, issue.12, pp.2013-2019, 2008.
DOI : 10.1200/JCO.2007.14.9930

K. Kawakami and G. Watanabe, Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene, Cancer Res, vol.63, pp.6004-6007, 2003.

L. Iyer, S. Das, L. Janisch, M. Wen, J. Ramirez et al., polymorphism as a determinant of irinotecan disposition and toxicity, Pharmacogenomics J, vol.2, pp.1-1, 2002.

M. Mohammadi, W. Ollier, and I. Hutchinson, A functional association study of VEGF gene promoter polymorphisms with VEGF expression by stimulated pbm cells, Human Immunology, vol.64, issue.10, p.125, 2003.
DOI : 10.1016/j.humimm.2003.08.234

T. Hansen and A. Jakobsen, Clinical implications of genetic variations in the VEGF system in relation to colorectal cancer, Pharmacogenomics, vol.12, issue.12, pp.1681-1693, 2011.
DOI : 10.2217/pgs.11.118

S. Kjaer-frifeldt, R. Fredslund, J. Lindebjerg, T. Hansen, K. Spindler et al., haplotype combinations in a stage II colon cancer population, Pharmacogenomics, vol.13, issue.7, pp.763-770, 2012.
DOI : 10.2217/pgs.12.38

K. Dassoulas, M. Gazouli, S. Rizos, G. Theodoropoulos, Z. Christoni et al., Common polymorphisms in the vascular endothelial growth factor gene and colorectal cancer development, prognosis, and survival, Molecular Carcinogenesis, vol.18, issue.6, pp.563-569, 2009.
DOI : 10.1002/mc.20495

T. Hansen, G. Spindler, K. Andersen, R. Lindebjerg, J. Brandslund et al., The predictive value of genetic variations in the vascular endothelial growth factor A gene in metastatic colorectal cancer, The Pharmacogenomics Journal, vol.13, issue.1, pp.53-60, 2011.
DOI : 10.1002/mc.20495

V. Formica, R. Palmirotta, M. Del, A. Savonarola, G. Ludovici et al., Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab, International Journal of Colorectal Disease, vol.24, issue.2, pp.143-151, 2011.
DOI : 10.1007/s00384-010-1108-1

P. Therasse, S. Arbuck, E. Eisenhauer, J. Wanders, R. Kaplan et al., New Guidelines to Evaluate the Response to Treatment in Solid Tumors, JNCI: Journal of the National Cancer Institute, vol.92, issue.3, pp.205-216, 2000.
DOI : 10.1093/jnci/92.3.205

A. Trotti, D. Colevas, A. Setser, V. Rusch, D. Jaques et al., CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment, Seminars in Radiation Oncology, vol.13, issue.3, pp.176-181, 2003.
DOI : 10.1016/S1053-4296(03)00031-6

N. Nief, M. Le, and R. J. , Involvement of gene polymorphisms of thymidylate synthase in gene expression, protein activity and anticancer drug cytotoxicity using the NCI-60 panel, European Journal of Cancer, vol.43, issue.5, pp.955-962, 2007.
DOI : 10.1016/j.ejca.2006.12.012

Y. Hochberg and Y. Benjamini, More powerful procedures for multiple significance testing, Statistics in Medicine, vol.63, issue.7, pp.811-818, 1990.
DOI : 10.1002/sim.4780090710

D. Pectasides, G. Papaxoinis, K. Kalogeras, A. Eleftheraki, I. Xanthakis et al., XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis, BMC Cancer, vol.7, issue.15s, p.271, 2012.
DOI : 10.1007/s11605-009-1035-z

J. Souglakos, N. Ziras, S. Kakolyris, I. Boukovinas, N. Kentepozidis et al., Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC), British Journal of Cancer, vol.18, issue.3, pp.453-459, 2012.
DOI : 10.1056/NEJMoa0805019

G. Stathopoulos, C. Batziou, D. Trafalis, J. Koutantos, S. Batzios et al., Treatment of Colorectal Cancer with and without Bevacizumab: A Phase III Study, Oncology, vol.78, issue.5-6, pp.376-381, 2010.
DOI : 10.1159/000320520

S. Kopetz, P. Hoff, J. Morris, R. Wolff, C. Eng et al., Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance, Journal of Clinical Oncology, vol.28, issue.3, pp.453-459, 2010.
DOI : 10.1200/JCO.2009.24.8252

M. Ducreux, A. Adenis, J. Pignon, E. Francois, B. Chauffert et al., Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: Final results from a randomised phase ii study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study), European Journal of Cancer, vol.49, issue.6, pp.1236-1245, 2013.
DOI : 10.1016/j.ejca.2012.12.011

E. Van-cutsem, F. Rivera, S. Berry, A. Kretzschmar, M. Michael et al., Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study, Annals of Oncology, vol.20, issue.11, pp.1842-1847, 2009.
DOI : 10.1093/annonc/mdp233

C. Fuchs, J. Marshall, and J. Barrueco, Randomized, Controlled Trial of Irinotecan Plus Infusional, Bolus, or Oral Fluoropyrimidines in First-Line Treatment of Metastatic Colorectal Cancer: Updated Results From the BICC-C Study, Journal of Clinical Oncology, vol.26, issue.4, pp.689-690, 2008.
DOI : 10.1200/JCO.2007.15.5390

J. Bendell, T. Bekaii-saab, A. Cohn, H. Hurwitz, M. Kozloff et al., Treatment Patterns and Clinical Outcomes in Patients With Metastatic Colorectal Cancer Initially Treated with FOLFOX-Bevacizumab or FOLFIRI-Bevacizumab: Results From ARIES, a Bevacizumab Observational Cohort Study, The Oncologist, vol.17, issue.12, pp.1486-1495, 2012.
DOI : 10.1634/theoncologist.2012-0190

F. Kabbinavar, J. Hambleton, R. Mass, H. Hurwitz, E. Bergsland et al., Combined Analysis of Efficacy: The Addition of Bevacizumab to Fluorouracil/Leucovorin Improves Survival for Patients With Metastatic Colorectal Cancer, Journal of Clinical Oncology, vol.23, issue.16, pp.3706-3712, 2005.
DOI : 10.1200/JCO.2005.00.232

B. Giantonio, P. Catalano, N. Meropol, O. Dwyer, P. Mitchell et al., Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200, Journal of Clinical Oncology, vol.25, issue.12, pp.1539-1544, 2007.
DOI : 10.1200/JCO.2006.09.6305

S. Welch, K. Spithoff, R. Rumble, and J. Maroun, Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review, Annals of Oncology, vol.21, issue.6, pp.1152-1162, 2010.
DOI : 10.1093/annonc/mdp533

L. Macedo, A. Lima, and A. Sasse, Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups, BMC Cancer, vol.305, issue.5, p.89, 2012.
DOI : 10.1001/jama.2011.51

B. Iacopetta, F. Grieu, D. Joseph, and H. Elsaleh, A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil, British Journal of Cancer, vol.5, issue.6, pp.827-830, 2001.
DOI : 10.1054/bjoc.2001.2007

G. Lurje, P. Manegold, Y. Ning, A. Pohl, W. Zhang et al., Thymidylate synthase gene variations: predictive and prognostic markers, Molecular Cancer Therapeutics, vol.8, issue.5, pp.1000-1007, 2009.
DOI : 10.1158/1535-7163.MCT-08-0219

E. Martinez-balibrea, A. Abad, A. Martinez-cardus, A. Gines, M. Valladares et al., UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy, British Journal of Cancer, vol.9, issue.4, pp.581-589, 2010.
DOI : 10.1093/bioinformatics/btl268

S. Pullarkat, J. Stoehlmacher, V. Ghaderi, Y. Xiong, S. Ingles et al., Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy, The Pharmacogenomics Journal, vol.1, issue.1, pp.65-70, 2001.
DOI : 10.2307/2281868

M. Vignoli, S. Nobili, C. Napoli, A. Putignano, M. Morganti et al., Thymidylate synthase expression and genotype have no major impact on the clinical outcome of colorectal cancer patients treated with 5-fluorouracil, Pharmacological Research, vol.64, issue.3, pp.242-248, 2011.
DOI : 10.1016/j.phrs.2011.04.006

J. Hoskins, R. Goldberg, P. Qu, J. Ibrahim, and H. Mcleod, UGT1A1*28 Genotype and Irinotecan-Induced Neutropenia: Dose Matters, JNCI Journal of the National Cancer Institute, vol.99, issue.17, pp.1290-1295, 2007.
DOI : 10.1093/jnci/djm115

D. Ruggiero, C. Dalmasso, T. Nutile, R. Sorice, L. Dionisi et al., Genetics of VEGF Serum Variation in Human Isolated Populations of Cilento: Importance of VEGF Polymorphisms, PLoS ONE, vol.42, issue.2, p.16982, 2011.
DOI : 10.1371/journal.pone.0016982.s004

M. Yamamori, T. Sakaeda, T. Nakamura, N. Okamura, T. Tamura et al., Association of VEGF genotype with mRNA level in colorectal adenocarcinomas, Biochemical and Biophysical Research Communications, vol.325, issue.1, pp.144-150, 2004.
DOI : 10.1016/j.bbrc.2004.10.005